Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.

Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, Rosano GM, Davis BR, Ridao M, Zaragoza A, Montero-Corominas D, Tobías A, de la Fuente-Honrubia C, Tabarés-Seisdedos R, Hutton B.

PLoS Med. 2016 Mar 8;13(3):e1001971. doi: 10.1371/journal.pmed.1001971. Review. Erratum in: PLoS Med. 2016 Jun;13(6):e1002064.

2.

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

Farsang C.

Vasc Health Risk Manag. 2011;7:605-22. doi: 10.2147/VHRM.S23468. Review.

3.

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.

Siragy HM.

Vasc Health Risk Manag. 2011;7:297-313. doi: 10.2147/VHRM.S15541. Review.

4.

Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.

Bangalore S, Kumar S, Wetterslev J, Messerli FH.

BMJ. 2011 Apr 26;342:d2234. doi: 10.1136/bmj.d2234. Review.

5.
6.

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

Galzerano D, Capogrosso C, Di Michele S, Bobbio E, Paparello P, Gaudio C.

Vasc Health Risk Manag. 2010 Aug 9;6:479-94. Review.

7.

Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan using RP HPLC.

Kokil SU, Bhatia MS.

Indian J Pharm Sci. 2009 Mar;71(2):111-4. doi: 10.4103/0250-474X.54270.

8.

Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.

Koh KK, Han SH, Oh PC, Shin EK, Quon MJ.

Atherosclerosis. 2010 Apr;209(2):307-13. doi: 10.1016/j.atherosclerosis.2009.09.007. Review.

10.

Valsartan in the treatment of heart attack survivors.

Jugdutt BI.

Vasc Health Risk Manag. 2006;2(2):125-38. Review.

11.
12.

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

British Cardiac Society.; British Hypertension Society.; Diabetes UK.; HEART UK.; Primary Care Cardiovascular Society.; Stroke Association..

Heart. 2005 Dec;91 Suppl 5:v1-52. No abstract available.

13.

Angiotensin receptor blockers and risk of myocardial infarction: systematic review.

McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT.

BMJ. 2005 Oct 15;331(7521):873. Review.

14.

Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed.

Opie LH.

BMJ. 2005 May 28;330(7502):1270; author reply 1270-1. No abstract available.

15.

Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.

Yousef ZR, Leyva F, Gibbs C.

BMJ. 2005 May 28;330(7502):1270; author reply 1270-1. No abstract available.

16.

Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate.

McMurray J.

BMJ. 2005 May 28;330(7502):1269; author reply 1270-1. No abstract available.

17.

Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.

Lewis EJ; Collaborative Study Group..

BMJ. 2005 May 28;330(7502):1269-70; author reply 1270-1. No abstract available.

Items per page

Supplemental Content

Support Center